DR. EOIN PETER COAKLEY, MD
Osteopathic Medicine at 18 St, San Francisco, CA

License number
California 81493
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
4675 18Th St, San Francisco, CA 94114
Phone
(415) 298-4984

Personal information

See more information about EOIN PETER COAKLEY at radaris.com
Name
Address
Phone
Eoin P Coakley
430 Mangels Ave, San Francisco, CA 94127

Professional information

Eoin Coakley Photo 1

Methods And Compositions For Determining Hypersusceptibility Of Hiv-1 To Non-Nucleoside Reverse Transcriptase Inhibitors

US Patent:
2012028, Nov 8, 2012
Filed:
May 9, 2012
Appl. No.:
13/467527
Inventors:
Neil T. Parkin - Belmont CA, US
Eoin Coakley - San Francisco CA, US
Assignee:
Monogram Biosciences, Inc. - South San Francisco CA
International Classification:
C12Q 1/70, G01N 21/64, A61P 31/18, A61K 31/551, A61K 31/496, G01N 27/26, A61K 31/536
US Classification:
514220, 435 5, 5142305, 51425309
Abstract:
This invention relates to methods for determining hypersusceptibility of HIV-1 viruses to non-nucleoside reverse transcriptase inhibitors (NNRTIs) based on the viral genotypes. The methods generally comprise detecting, in a gene encoding reverse transcriptase of the HIV-1, the presence of a mutation at codon 65, 69, or 74 alone or in combination with one or more mutations at certain other codons. Combinations of mutations associated with hypersusceptibility to NNRTIs are also disclosed.


Eoin Coakley Photo 2

Methods And Compositions For Determining Hypersusceptibility Of Hiv-1 To Non-Nucleoside Reverse Transcriptase Inhibitors

US Patent:
2009020, Aug 20, 2009
Filed:
Feb 16, 2006
Appl. No.:
11/884667
Inventors:
Neil T. Parkin - Belmont CA, US
Eoin Coakley - San Francisco CA, US
International Classification:
C12Q 1/70
US Classification:
435 5
Abstract:
This invention relates to methods for determining hypersusceptibility of HIV-1 viruses to non-nucleoside reverse transcriptase inhibitors (NNRTIs) based on the viral genotypes. The methods generally comprise detecting, in a gene encoding reverse transcriptase of the HIV-1, the presence of a mutation at codon 65, 69, or 74 alone or in combination with one or more mutations at certain other codons. Combinations of mutation associated with hypersusceptibility to NNRTIs are also disclosed.